Loading…
Loading…
Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase Medical device veteran poised to lead STRATA to market leadership and continued revenue growth as Company continues next development phase
Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling continued market growth and expanding indications Multicenter prospective RCT published in JAAD confirms superiority of XTRAC® Excimer Laser plus oral JAK inhibitors over tacrolimus combination therapy in children aged 2–18 years with progressive vitiligo, fueling continued market growth and expanding indications
Strata Skin Sciences, Inc. (NASDAQ: SSKN - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 679,358 shares, an increase of 89.2% from the January 29th total of 358,994 shares. Currently, 19.5% of the company's shares are sold
Strata Skin Sciences (NASDAQ: SSKN - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Institutional and Insider Ownership 32.4%
Strata Skin Sciences (NASDAQ: SSKN - Get Free Report) and Clover Health Investments (NASDAQ: CLOV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Institutional and Insider Ownership 32.4%
HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and confirms that trading of the Company's common stock has been suspended from trading on The Nasdaq Capital Market (“Nasdaq”) at the opening of business on February 19, 2026. The Company also expects to file a Form 15 with the SEC on or about March 2, 2026, to commence the process of terminating the registration of its common stock under Section 12(g) of the Exchange Act and to suspend the Company's reporting obligations under Sections 13(a) and 15(d) of the Exchange Act, which we refer to as “going dark”.
STRATA Skin Sciences plunges 8% despite new meta-analysis backing its 308 nm excimer laser with up to 85% PASI improvement in plaque psoriasis.
HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatment offerings.